RLYB - יחס חוב להיוון בספרים rallybio.com

Rallybio Corporation (RLYB) develops unique therapies for rare fetal and hematological pathologies. The specific clinical environment ensures complete patient loyalty, although growth rates depend on FDA decisions. Optimizing global biologics supplies reduces customs risks, and the ratio of attracted funds to book capitalization demonstrates interest rate resilience, where the value of 0.00 expresses the metric level.

Rallybio Corporation focuses on developing drugs for rare diseases through contract organizations. This indicator determines the share of borrowed funds in the total value of assets minus liabilities. Analyzing the ratio of total liabilities to book capitalization allows for an assessment of the business's degree of financial autonomy. A decrease in this coefficient confirms the stability of the operating model during the standard functioning of R&D. The asset is categorized as a high-risk biopharmaceutical instrument.